stockrowEmergent Biosolutions Inc.
EBS Healthcare Drug Manufacturers Specialty & Generic
Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024.
- Revenue
- −52.4%
- EPS
- −166.4%
- Free cash flow
- +1,893.0%
- Total debt
- −23.4%
Quarter to September 2026, against a year earlier
Follow EBS
Alert me
Emergent Biosolutions Inc. (EBS) EV/Sales
As of 5 November 2026, Emergent Biosolutions Inc. (EBS) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.8× (April 2025) to 6.1× (August 2020); the current reading is higher than 15% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | 35.13% |
| FY2024 | 1.0× | 21.60% |
| FY2023 | 0.8× | (31.27%) |
| FY2022 | 1.2× | (16.34%) |
| FY2021 | 1.5× | (54.39%) |
| FY2020 | 3.2× | 3.50% |
| FY2019 | 3.1× | (33.72%) |
| FY2018 | 4.7× | 42.15% |
| FY2017 | 3.3× | 22.07% |
| FY2016 | 2.7× | (11.37%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.0× | (9.02%) |
| Jun 2026 | 1.1× | (8.96%) |
| Mar 2026 | 1.2× | (9.65%) |
| Dec 2025 | 1.4× | 23.14% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −7.2× |
| EBS Emergent Biosolutions Inc. | 1.0× |
| CGC Canopy Growth Corporation compare | 1.0× |
| ACB Aurora Cannabis Inc. compare | 1.3× |
| KMDA Kamada Ltd. compare | 1.8× |
| ADCT ADC Therapeutics SA compare | 1.9× |
| ANIK Anika Therapeutics Inc. compare | 2.0× |
| LFCR Lifecore Biomedical, Inc. compare | 3.6× |
| SIGA Siga Technologies Inc. compare | 4.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)